Stock PRN PROFOUND MEDICAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News Profound Medical Corp.

Equities

PRN

CA74319B5027

Market Closed - Toronto S.E.
Other stock markets
 15:59:58 2024-05-16 EDT 		5-day change 1st Jan Change
11.51 CAD -0.09% Intraday chart for Profound Medical Corp. -1.12% +3.69%
05-15 Transcript : Profound Medical Corp. - Shareholder/Analyst Call
05-14 Sector Update: Health Care Stocks Steady Premarket Tuesday MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTS
AQ
Transcript : Profound Medical Corp. - Shareholder/Analyst Call
Sector Update: Health Care Stocks Steady Premarket Tuesday
MT
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell
MT
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module
MT
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan
MT
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
AQ
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan
CI
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance
MT
Transcript : Profound Medical Corp., Q1 2024 Earnings Call, May 09, 2024
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue
MT
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance
MT
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
AQ
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024
CI
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer
MT
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"
MT
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"
MT
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
AQ
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
AQ
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRN Stock
  4. News Profound Medical Corp.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW